Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA

被引:0
|
作者
McKeage K. [1 ]
Lyseng-Williamson K.A. [1 ]
机构
[1] Springer, Private Bag 65901, Mairangi Bay, Auckland
关键词
D O I
10.1007/s40267-017-0448-0
中图分类号
学科分类号
摘要
Linaclotide (Linzess®) is a synthetic guanylate cyclase C agonist that acts locally in the gastrointestinal tract to increase intestinal fluid levels, increase colonic transit, and reduce peripheral pain. In adults with constipation-predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC), once-daily oral linaclotide 290 µg (IBS-C), or 145 or 72 µg (CIC), significantly improved stool frequency and consistency, abdominal pain and bloating, and health-related quality-of-life. Linaclotide is generally well tolerated and, consistent with its therapeutic action, diarrhea is the most common adverse event. © 2017, Springer International Publishing AG.
引用
收藏
页码:497 / 504
页数:7
相关论文
共 50 条
  • [41] Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation
    Abrahamsson, Hasse
    Ostlund-Lindqvist, Ann-Margret
    Nilsson, Ralf
    Simren, Magnus
    Gillberg, Per-Goran
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2008, 43 (12) : 1483 - 1488
  • [42] Constipation and Constipation-predominant Irritable Bowel Syndrome: A Comparative Study Using Rome III Criteria
    Rajindrajith, Shaman
    Devanarayana, Niranga M.
    Benninga, Marc A.
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (05): : 679 - 684
  • [43] CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME AND FUNCTIONAL CONSTIPATION ARE NOT DISCRETE DISORDERS: A MACHINE LEARNING APPROACH
    Ruffle, James
    Tinkler, Linda
    Emmett, Christopher
    Ford, Alex
    Nachev, Parashkev
    Aziz, Qasim
    Farmer, Adam
    Yiannakou, Yan
    [J]. GUT, 2021, 70 : A218 - A218
  • [44] White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
    Nan, Jiaofen
    Zhang, Liangliang
    Chen, Qiqiang
    Zong, Nannan
    Zhang, Peiyong
    Ji, Xing
    Ma, Shaohui
    Zhang, Yuchen
    Huang, Wei
    Du, Zhongzhou
    Xia, Yongquan
    Zhang, Ming
    [J]. JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 24 (01) : 107 - 118
  • [45] Cisapride treatment of constipation-predominant irritable bowel syndrome is not superior to placebo
    Ziegenhagen, DJ
    Kruis, W
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2004, 19 (07) : 744 - 749
  • [46] Constipation-Predominant Irritable Bowel Syndrome Complicating Asymptomatic Nonrotation of the Midgut
    Plackett, Timothy P.
    Myers, Jonathan
    Gagliano, Ronald A., Jr.
    [J]. JOURNAL OF THE AMERICAN OSTEOPATHIC ASSOCIATION, 2010, 110 (08): : 437 - 440
  • [47] Potential effects of sodium hyaluronate on constipation-predominant irritable bowel syndrome
    Cui, Li
    Zou, Shuting
    Liu, Jing
    Lv, Huixia
    Li, Hui
    Zhang, Zhenhai
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 127
  • [48] Novel investigational drugs for constipation-predominant irritable bowel syndrome: a review
    Mosinska, Paula
    Salaga, Maciej
    Fichna, Jakub
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (03) : 275 - 286
  • [49] Current and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome
    Biniszewska, Olga
    Jacenik, Damian
    Tarasiuk, Aleksandra
    Fichna, Jakub
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (08) : 1039 - 1049
  • [50] Colchicine Plus Olsalazine for Treatment of Constipation-Predominant Irritable Bowel Syndrome
    Barody, Thomas J.
    Hills, Lauren A.
    Torres, Margaux
    [J]. GASTROENTEROLOGY, 2009, 136 (05) : A484 - A484